Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change

Executive Summary

The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.

Advertisement

Related Content

Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
Deals Of The Week Looks At Pricing Conundrums
Forest Cuts A New Path But Remains Rooted In Primary Care
APA Update: New Antidepressants Elbow Into Crowded Market
Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
FDA Creates Exclusivity Board To Help Resolve Vexing Questions
Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant
FDA Clears Forest’s Savella, The First Fibromyalgia-Only Drug
Enantiomers, Antibiotics May Benefit As Hatch Pushes Incentives In FDA Bill
FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel